Biotech

Biotech

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

By Rebecca Robbins

STAT Summit

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

By STAT staff

Biotech

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

By Nicholas Florko

Biotech

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

By Kate Sheridan

Biotech

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

By Kate Sheridan

Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Biotech

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

By Adam Feuerstein

Biotech

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

By Kate Sheridan

Biotech

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

By Damian Garde

Biotech

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

By Kate Sheridan

Biotech

First CRISPR treatment for blood diseases shows early benefits in two patients

By Sharon Begley and Adam Feuerstein

Biotech

Novo Nordisk’s parent company to launch research incubator in Boston

By Kate Sheridan

Biotech

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

By Chris Morrison

Biotech

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth

By Kate Sheridan

Biotech

A new approach to treating schizophrenia delivers positive results in mid-stage trial

By Adam Feuerstein

Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Biotech

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Biotech

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

By Adam Feuerstein

Biotech

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

By Nicholas Florko

Biotech

Immunotherapies targeting melanoma post encouraging results, new data show

By Adam Feuerstein

Biotech

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill

By Adam Feuerstein

Detailed data on Biogen’s resurrected Alzheimer’s drug raise more questions than answers

Sage’s new antidepressant faces major setback in new study

Eli Lilly places the team from a startup it bought in January in charge of its cancer research

Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s

This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too

Startup Spotlight: Juno, Vir alum starts a new immunotherapy company

Enlight Biosciences was going to ‘transform pharma R&D.’ What happened?

Global Blood secures FDA approval for new pill to treat sickle cell disease

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug

‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation

Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’

FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

First CRISPR treatment for blood diseases shows early benefits in two patients

Novo Nordisk’s parent company to launch research incubator in Boston

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Alkermes buys Rodin Therapeutics for up to $950 million, giving it possible avenue for growth

A new approach to treating schizophrenia delivers positive results in mid-stage trial

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

When bio-Twitter greets a sincere thread with snark, what can a Silicon Valley VC say?

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Solid Biosciences’ Duchenne gene therapy trial halted after patient suffers serious toxicity

It’s tiny biotechs — not big drug makers — that fear ‘nuclear winter’ from Pelosi’s drug pricing bill

Immunotherapies targeting melanoma post encouraging results, new data show

Fibrogen discloses new data that eases heart-safety concerns about experimental anemia pill